Answers are grounded in this paper and cite their sources.
OBJECTIVE: Present an interim update on the reporting and representation of sociodemographic data in eating disorder psychotherapeutic treatment trials in the United States from 2021 to 2026 and discuss challenges that arose during screening and data synthesis. Provide recommendations to improve trial reporting to facilitate ongoing systematic evaluation of representation. METHOD: PRISMA guidelines for systematic reviews were followed. Eligible studies were randomized controlled psychotherapeutic eating disorder treatment trials in the efficacy or effectiveness stage with at least one US site published from 2021 to mid-2026. Two independent raters screened and extracted data. We calculated pooled estimates to evaluate representation. RESULTS: Our search yielded 1343 studies for screening; eight were deemed eligible. Screening challenges arose due to participant location ambiguity, lack of by-country demographic data, and ambiguity in intervention development stage. Trials were predominantly focused on young adult, female populations and disproportionately targeted binge-eating spectrum disorders and high weight. Sexual orientation and diverse gender identities were not assessed. We observed some indication of increased racial diversity, but Black participants remained markedly underrepresented. DISCUSSION: Representation estimates should be interpreted with caution due to small sample size. We observed some signals of progress in sociodemographic representation, but also continued areas of stagnation (e.g., age diversity). To facilitate future evaluation of sociodemographic representation, we provide recommendations for clinical trial conduct and reporting, including improved transparency in participant location and intervention stage.
No takes yet. Share an insight, caveat, or question.
Burnette et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: